|
[1]
|
Carmeliet P. Angiogenesis in life, disease and medicine[J]. Nature, 2005, 438 (7070): 932-936. doi: 10.1038/nature04478
|
|
[2]
|
Folkman J. Angiogenesis in cancer, vascular, rheumatoid and otherdisease[J]. Nat Med, 1995, 1 (1): 27-31. doi: 10.1038/nm0195-27
|
|
[3]
|
Maniotis AJ, Folberg R, Hess A, et al. Vascular channel formationby human melanoma cells in vivo and in vitro: vasculogenic mimicry[J]. Am J Pathol, 1999, 155 (3): 739-752. doi: 10.1016/S0002-9440(10)65173-5
|
|
[4]
|
Fausto N. Vasculogenic mimicry in tumors. Fact or artifact[J]? Am JPathol, 2000, 156 (2): 359.
|
|
[5]
|
McDonald DM, Munn L, Jain RK. Vasculogenic mimicry: howconvincing, how novel, and how significant[J]? Am J Pathol, 2000, 156 (2): 383-388.
|
|
[6]
|
Shirakawa K, Kobayashi H, Heike Y, et al. Hemodynamics in vasculogenic mimicry and angiogenesis of inflammatory breast cancerxenograft[J]. Cancer Res, 2002, 62 (2): 560-566.
|
|
[7]
|
van der Schaft DW, Hillen F, Pauwels P, et al. Tumor cell plasticityin Ewing sarcoma, an alternative circulatory system stimulated byhypoxia[J]. Cancer Res, 2005, 65 (24): 11520-11528. doi: 10.1158/0008-5472.CAN-05-2468
|
|
[8]
|
Chung LW, Baseman A, Assikis V, et al. Molecular insights intoprostate cancer progression: the missing link of tumor microenvironment[J]. J Urol, 2005, 173 (1): 10-20. doi: 10.1097/01.ju.0000141582.15218.10
|
|
[9]
|
Su M, Feng YJ, Yao LQ, et al. Plasticity of ovarian cancer cellSKOV3ip and vasculogenic mimicry in vivo[J]. Int J Gynecol Cancer, 2008, 18 (3): 476-486. doi: 10.1111/j.1525-1438.2007.01034.x
|
|
[10]
|
Passalidou E, Trivella M, Singh N, et al. Vascular phenotype in angiogenic and non-angiogenic lung non-small cell carcinomas[J]. BrJ Cancer, 2002, 86 (2): 244-249. doi: 10.1038/sj.bjc.6600015
|
|
[11]
|
Guzman G, Cotler SJ, Lin AY, et al. A pilot study of vasculogenicmimicry immunohistochemical expression in hepatocellular carcinoma[J]. Arch Pathol Lab Med, 2007, 131 (12): 1776-1781. doi: 10.5858/2007-131-1776-APSOVM
|
|
[12]
|
El Hallani S, Boisselier B, Peglion F, et al. A new alternative mechanism in glioblastoma vascularization: tubular vasculogenic mimicry[J]. Brain, 2010, 133 (Pt 4): 973-982.
|
|
[13]
|
Sun B, Zhang S, Zhao X, et al. Vasculogenic mimicry is associatedwith poor survival in patients with mesothelial sarcomas and alveolar rhabdomyosarcomas[J]. Int J Oncol, 2004, 25 (6): 1609-1614.
|
|
[14]
|
Sun B, Qie S, Zhang S, et al. Role and mechanism of vasculogenicmimicry in gastrointestinal stromal tumors[J]. Hum Pathol, 2008, 39 (3): 444-451. doi: 10.1016/j.humpath.2007.07.018
|
|
[15]
|
Li M, Gu Y, Zhang Z, et al. Vasculogenic mimicry: a new prognostic sign of gastric adenocarcinoma[J]. Pathol Oncol Res, 2010, 16 (2): 259-266. doi: 10.1007/s12253-009-9220-7
|
|
[16]
|
Vartanian AA, Stepanova EV, Gutorov SL, et al. Prognostic significance of periodic acid-Schiff-positive patterns in clear cell renalcell carcinoma[J]. Can J Urol, 2009, 16 (4): 4726-4732.
|
|
[17]
|
Sun T, Zhao N, Zhao XL, et al. Expression and functional significance of Twist1 in hepatocellular carcinoma: its role in vasculogenic mimicry[J]. Hepatology, 2010, 51 (2): 545-556. doi: 10.1002/hep.23311
|
|
[18]
|
Fan YZ, Sun W, Zhang WZ, et al. Vasculogenic mimicry in humanprimary gallbladder carcinoma and clinical significance thereof[J]. Zhonghua Yi Xue Za Zhi, 2007, 87 (3): 145-149.
|
|
[19]
|
Baeten CI, Hillen F, Pauwels P, et al. Prognostic role of vasculogenic mimicry in colorectal cancer[J]. Dis Colon Rectum, 2009, 52 (12): 2028-2035. doi: 10.1007/DCR.0b013e3181beb4ff
|
|
[20]
|
Hendrix MJ, Seftor EA, Meltzer PS, et al. Expression and functionalsignificance of VE-cadherin in aggressive human melanoma cells: role in vasculogenic mimicry[J]. Proc Natl Acad Sci U S A, 2001, 98 (14): 8018-8023. doi: 10.1073/pnas.131209798
|
|
[21]
|
Wang R, Chadalavada K, Wilshire J, et al. Glioblastoma stem-likecells give rise to tumour endothelium[J]. Nature, 2010, 468 (7325): 829-833. doi: 10.1038/nature09624
|
|
[22]
|
Ricci-Vitiani L, Pallini R, Biffoni M, et al. Tumour vascularizationvia endothelial differentiation of glioblastoma stem-like cells[J]. Nature, 2010, 468 (7325): 824-828.
|
|
[23]
|
Mani SA, Guo W, Liao MJ, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells[J]. Cell, 2008, 133 (4): 704-715. doi: 10.1016/j.cell.2008.03.027
|
|
[24]
|
Yang MH, Hsu DS, Wang HW, et al. Bmi1 is essential inTwist1-induced epithelial-mesenchymal transition[J]. Nat Cell Biol, 2010, 12 (10): 982-992. doi: 10.1038/ncb2099
|
|
[25]
|
Maeda M, Shintani Y, Wheelock MJ, et al. Src activation is not necessary for transforming growth factor (TGF) -beta-mediated epithelialto mesenchymal transitions (EMT) in mammary epithelial cells. PP1directly inhibits TGF-beta receptorsⅠandⅡ[J]. J Biol Chem, 2006, 281 (1): 59-68. doi: 10.1074/jbc.M503304200
|
|
[26]
|
Liu Z, Qi L, Li H, et al. Zinc finger E-box binding homeobox 1promotes vasculogenic mimicry in colorectal cancer through induction of epithelial-to-mesenchymal transition[J]. Cancer Sci, 2012, 103 (4): 813-820. doi: 10.1111/j.1349-7006.2011.02199.x
|
|
[27]
|
Hess AR, Seftor EA, Gruman LM, et al. VE-cadherin regulatesEphA2 in aggressive melanoma cells through a novel signaling pathway: implications for vasculogenic mimicry[J]. Cancer Biol Ther, 2006, 5 (2): 228-233. doi: 10.4161/cbt.5.2.2510
|
|
[28]
|
Sun B, Zhang D, Zhang S, et al. Hypoxia influences vasculogenicmimicry channel formation and tumor invasion-related protein ex pression in melanoma[J]. Cancer Lett, 2007, 249 (2): 188-197. doi: 10.1016/j.canlet.2006.08.016
|
|
[29]
|
Zhang S, Li M, Zhang D, et al. Hypoxia influences linearly patterned programmed cell necrosis and tumor blood supply patternsformation in melanoma[J]. Lab Invest, 2009, 89 (5): 575-86. doi: 10.1038/labinvest.2009.20
|
|
[30]
|
娄丹, 韩春荣, 赵秀兰, 等. 黑色素瘤中线形程序性坏死与血管生成及预后关系的初步探讨[J]. 中国肿瘤临床, 2010, 37 (2): 80-84. doi: 10.3969/j.issn.1000-8179.2010.02.005
|
|
[31]
|
Ruf W, Seftor EA, Petrovan RJ, et al. Differential role of tissue factor pathway inhibitors 1 and 2 in melanoma vasculogenic mimicry[J]. Cancer Res, 2003, 63 (17): 5381-5389.
|
|
[32]
|
Hess AR, Postovit LM, Margaryan NV, et al. Focal adhesion kinasepromotes the aggressive melanoma phenotype[J]. Cancer Res, 2005, 65 (21): 9851-9860. doi: 10.1158/0008-5472.CAN-05-2172
|
|
[33]
|
Hess AR, Seftor EA, Seftor RE, et al. Phosphoinositide 3-kinaseregulates membrane Type 1-matrix metalloproteinase (MMP) andMMP-2 activity during melanoma cell vasculogenic mimicry[J]. Cancer Res, 2003, 63 (16): 4757-4762.
|
|
[34]
|
Robertson GP. Mig-7 linked to vasculogenic mimicry[J]. Am J Pathol, 2007, 170 (5): 1454-1456. doi: 10.2353/ajpath.2007.070127
|
|
[35]
|
Topczewska JM, Postovit LM, Margaryan NV, et al. Embryonic andtumorigenic pathways converge via Nodal signaling: role in melanomaaggressiveness[J]. Nat Med, 2006, 12 (8): 925-932. doi: 10.1038/nm1448
|
|
[36]
|
Basu GD, Liang WS, Stephan DA, et al. A novel role for cyclooxygenase-2 in regulating vascular channel formation by human breastcancer cells[J]. Breast Cancer Res, 2006, 8 (6): R69. doi: 10.1186/bcr1626
|
|
[37]
|
Heath VL, Bicknell R. Anticancer strategies involving the vasculature[J]. Nat Rev Clin Oncol, 2009, 6 (7): 395-404. doi: 10.1038/nrclinonc.2009.52
|
|
[38]
|
Paez-Ribes M, Allen E, Hudock J, et al. Antiangiogenic therapy elicitsmalignant progression of tumors to increased local invasion and distantmetastasis[J]. Cancer Cell, 2009, 15 (3): 220-231. doi: 10.1016/j.ccr.2009.01.027
|
|
[39]
|
Carbone C, Moccia T, Zhu C, et al. Anti-VEGF treatment-resistantpancreatic cancers secrete proinflammatory factors that contribute tomalignant progression by inducing an EMT cell phenotype[J]. ClinCancer Res, 2011, 17 (17): 5822-5832.
|
|
[40]
|
Ebos JM, Lee CR, Cruz-Munoz W, et al. Accelerated metastasis aftershort-term treatment with a potent inhibitor of tumor angiogenesis[J]. Cancer Cell, 2009, 15 (3): 232-239. doi: 10.1016/j.ccr.2009.01.021
|
点击查看大图
下载:
